首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Cancer Biology & Therapy

Cancer Biology & Therapy杂志,由Landes Bioscience出版,于2002年创刊,Monthly,出版语言English,ISSN:1538-4047,E-ISSN:1555-8576。

投稿咨询
Cancer Biology & Therapy
Cancer Biology & Therapy
Cancer Biology & Therapy
SCI SCIE

杂志介绍

JCR分区
Q1
中科院分区
2区
影响因子
5.7
CiteScore
8.4
期刊收录
SCI、SCIE

Cancer Biology & Therapy(中文译名:《癌症生物学与治疗》),ISSN:1538-4047,EISSN:1555-8576,是Landes Bioscience出版的国际性学术期刊,创刊于2002年,以Monthly形式稳定发行,2026年总发文量约81篇。该刊采用非OA开放访问,学科归属为医学 - 肿瘤学。该刊是医学、肿瘤学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达5.7,2025年期刊CiteScore为8.4,2025年期刊自引率约0%,在中科院期刊分区体系中位列医学大类2区,在所属学科领域具备高学术影响力与国际认可度。Cancer Biology & Therapy长期聚焦医学、肿瘤学及相关产业的技术应用前沿,平均审稿周期约2.3月,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、肿瘤学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,CHINA MAINLANDUSA、Italy、India、Japan、England、GERMANY (FED REP GER)等为核心发文国家与地区;ZHENGZHOU UNIVERSITYSHANGHAI JIAO TONG UNIVERSITY、SHANDONG UNIVERSITY、TIANJIN MEDICAL UNIVERSITY、VIRGINIA COMMONWEALTH UNIVERSITY、CHINA MEDICAL UNIVERSITY、CHINESE ACADEMY OF MEDICAL SCIENCES - PEKING UNION MEDICAL COLLEGE等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
ONCOLOGY 肿瘤学
3区
否 否

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
ONCOLOGY 肿瘤学
3区
否 否

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
4区
ONCOLOGY 肿瘤学
4区
否 否

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q1 72 / 333

78.5

学科:ONCOLOGY SCIE Q1 65 / 333

80.63

2024-2025年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q1 82 / 328

75.2

学科:ONCOLOGY SCIE Q1 79 / 328

76.07


中国学者近期发文

1
Molecular mechanisms and therapeutic strategies: DNA methylation in pancreatic cance

Author:Liu, Junlin; Xie, Junhua; Ding, Yunyu

Journal: CANCER BIOLOGY & THERAPY. 2026; Vol. 27, Issue 1, pp. -. DOI: 10.1080/15384047.2026.2644667

2
Real-world efficacy of Bruton tyrosine kinase inhibitor based maintenance therapy in diffuse large B-cell lymphoma: a multicenter retrospective cohort study with external historical contro

Author:Lyu, Li-Wei; Yao, Na; Liu, Zi-Xian; Wang, Yan-Ying; Li, Jie; Zhou, He-Bing; Li, Li-Hong; Li, Zhen-Ling; Wang, Liang

Journal: CANCER BIOLOGY & THERAPY. 2026; Vol. 27, Issue 1, pp. -. DOI: 10.1080/15384047.2026.2662031

3
Advances in natural killer cell immunotherapy for hematologic malignancie

Author:Hu, Huijie; Xiong, Yan; Xia, Minxin; Sheng, Lixia

Journal: CANCER BIOLOGY & THERAPY. 2026; Vol. 27, Issue 1, pp. -. DOI: 10.1080/15384047.2026.2658896

4
Research progress on the compositional characteristics of the tumor immune microenvironment and immunopredictive models in esophageal squamous cell carcinom

Author:Wang, Gongcheng; Li, Zhenzhen; Tan, Siyu; Ma, Jing; Yin, Zhiyong; Du, Juan; Fan, Linni

Journal: CANCER BIOLOGY & THERAPY. 2026; Vol. 27, Issue 1, pp. -. DOI: 10.1080/15384047.2026.2641263

5
The role of copper and cuproptosis in digestive system cancers: novel therapeutic strategies and mechanistic insight

Author:Xu, Guoshuai; Yao, Nan; Cheng, Renjia; Yang, Lin; Han, Fuzhou; Qu, Jun; Li, Wenqiang

Journal: CANCER BIOLOGY & THERAPY. 2026; Vol. 27, Issue 1, pp. -. DOI: 10.1080/15384047.2026.2644674

6
Deguelin inhibits perineural invasion in esophageal squamous cell carcinoma via targeting BDNF/TrkB axi

Author:Wei, Qiying; Bai, Liuyang; Yan, Liangying; Wang, Zhongyu; Jin, Rongyao; Li, Bingjie; Cao, Wenbo; Mo, Saijun

Journal: CANCER BIOLOGY & THERAPY. 2026; Vol. 27, Issue 1, pp. -. DOI: 10.1080/15384047.2026.2644788

7
The MYBL2-GTSE1 axis promotes laryngeal squamous cell carcinoma progression by regulating PI3K/AKT-dependent glycolytic reprogrammin

Author:Liang, Yiyin; Wang, Cansi; Ren, Tianjiao; Zhang, Bo; Liu, Yaqi; Fu, Rong; Feng, Juan

Journal: CANCER BIOLOGY & THERAPY. 2026; Vol. 27, Issue 1, pp. -. DOI: 10.1080/15384047.2026.2648193

8
Epigenetic silencing L3MBTL4 sensitizes esophageal cancer to DNA-PKcs inhibito

Author:Li, Yuan; Gao, Aiai; Yao, Yuanxin; Zhang, Meiying; Jin, Lianlian; Tao, Qian; Guo, Mingzhou

Journal: CANCER BIOLOGY & THERAPY. 2026; Vol. 27, Issue 1, pp. -. DOI: 10.1080/15384047.2026.2646393

9
ENPP3 drives ccRCC progression by cGAMP hydrolysis and STING-IFN suppressio

Author:Ma, Jiaxing; Wu, Yayun; Lin, Guangzheng; Sun, Xin; Geng, Hao; Zhang, Tao; Yu, Dexin

Journal: CANCER BIOLOGY & THERAPY. 2026; Vol. 27, Issue 1, pp. -. DOI: 10.1080/15384047.2026.2632995

10
Glutamine transporter SLC1A5 inhibits autophagy-mediated CD276 degradation to promote esophageal cancer progressio

Author:Wang, Chunyan; Zhang, Hongyan; Guan, Chaonan; Li, Yuying; Yang, Shengli; Huang, Lan

Journal: CANCER BIOLOGY & THERAPY. 2026; Vol. 27, Issue 1, pp. -. DOI: 10.1080/15384047.2026.2621606


在线咨询

Cancer Biology & Therapy

国际简称:CANCER BIOL THER参考译名:癌症生物学与治疗

年发文量:81 CiteScore:8.4 是否预警:否 Gold OA文章占比:100.00% 研究类文章占比:82.72%

杂志社联系方式:LANDES BIOSCIENCE, 1002 WEST AVENUE, 2ND FLOOR, AUSTIN, USA, TX, 78701

Cancer Biology & Therapy